Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STROACT
2024-518509-17-00Phase 2Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tissue-plasminogen activator and andexanet alfa in ischemic stroke (2 arms), sponsored by Medical University of Gdańsk. Primary endpoints: Occurrence of thrombotic events and death (interventional part) and Functional outcome by mRS at 90 days (observational part). Planned start Dec 2024; status: authorised.
02
Drugs
tissue-plasminogen activatorandexanet alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-518509-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518509-17-00.